Thierry Chauche
Financieel Directeur/CFO bij SAGIMET BIOSCIENCES INC.
Profiel
Mr. Thierry Chauche is a Chief Financial & Accounting Officer at Sagimet Biosciences, Inc. Mr. Chauche was previously employed as a Chief Financial Officer by Provention Bio, Inc. and a VP, Head-Strategic Financial Planning & Analysis by Alexion Pharmaceuticals, Inc. He received his graduate degree from école Des Ponts Paristec and an MBA from The Wharton School of the University of Pennsylvania.
Actieve functies van Thierry Chauche
| Bedrijven | Functie | Begin |
|---|---|---|
| SAGIMET BIOSCIENCES INC. | Financieel Directeur/CFO | 06-05-2024 |
Eerdere bekende functies van Thierry Chauche
| Bedrijven | Functie | Einde |
|---|---|---|
| PROVENTION BIO, INC. | Financieel Directeur/CFO | 01-04-2023 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01-01-2021 |
Opleiding van Thierry Chauche
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| école Des Ponts Paristec | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| SAGIMET BIOSCIENCES INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Provention Bio, Inc.
 Provention Bio, Inc. Pharmaceuticals: MajorHealth Technology Provention Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D), PRV-015 for the treatment of gluten-free diet non-responding celiac disease, PRV-6527 for Crohn’s disease, PRV-3279 for the treatment of lupus, and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Red Bank, NJ. | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |